[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatecellular-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatecellular-carcinoma":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,38,73,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100630053","efficacy-and-safety-of-camrelizumab-plus-rivoceranib-and-local-therapy-for-hepatocellular-carcinoma-with-lung-metastases-caplocal--a-multicentre-single-armprospective-cohort-study-100630053",false,"NCT07482670","Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases (CAPLocal) : A Multicentre, Single-Arm,Prospective Cohort Study","Inclusion Criteria:\n\nPatients must meet all of the following inclusion criteria in order to be eligible for participation in this study:\n\n1. The patient voluntarily participates in this study and signs an informed consent form.\n2. Age: 18 to 85 years old, both male and female are eligible.\n3. Patients with hepatocellular carcinoma (HCC) confirmed through histopathological examination of tumor tissue or imaging assessments \\[refer to the Guidelines for the Diagnosis and Treatment of Primary Hepatocellular Carcinoma (2024 Edition)\\].\n4. There are extrahepatic pulmonary metastases that have not been treated locally, and the number of these metastases is ≤5.\n5. Has not received any form of systematic treatment for HCC.\n6. There must be at least one measurable lesion (according to the RECIST v1.1 criteria, this measurable lesion must have a longitudinal diameter ≥ 10 mm on spiral CT scans or a short diameter ≥ 15 mm for enlarged lymph nodes; lesions that have previously received local treatment and have clearly progressed according to the RECIST v1.1 standards can be considered target lesions).\n7. Neutrophil-to-lymphocyte ratio (NLR) of less than or equal to 3.\n8. The Child Pugh liver function classification is Grade A or B (≤7).\n9. The Eastern Cooperative Oncology Group (ECOG) behavioral status is 0 or 1 for patients in the eastern United States.\n10. Good lung function, expected to be able to tolerate surgery or localized treatment.\n11. Other major organ functions are generally normal (the blood system, kidneys, etc., function well).\n\n    Muscular marrow function is adequate: white blood cell count ≥ 4.0 × 10\\^9\u002FL, absolute neutrophil count (ANC) ≥ 2.0 × 10\\^9 \u002F L, platelet count ≥ 100 × 10 \\^ 9 \u002F L, hemoglobin concentration ≥ 90 g\u002FL (no blood transfusions, no use of hematopoietic factors, and no medication correction within 2 weeks prior to the first administration).\n\n    For patients not receiving anticoagulant therapy, the INR (International Normalized Ratio) and APTI (Activated Partial Thromboplastin Time) values are ≤ 1.5 times the upper limit of normal.\n\n    Sufficient renal function: creatinine clearance ≥ 60 mL\u002Fmin.\n12. Patients with active hepatitis B virus (HBV) infection must receive anti-HBV treatment prior to the initiation of the study treatment and must be willing to undergo antiviral therapy throughout the study period. Patients with hepatitis C virus (HCV) RNA-positive status must receive antiviral treatment according to local standard treatment guidelines and have liver function levels within the range of CTCAE Grade 1 elevation.\n13. Women of childbearing age should have a negative serum or urine pregnancy test within 7 days prior to enrollment in the study, and must be non-lactating patients who have given their consent to use contraceptive measures during the study period and for 6 months after its completion. Men must agree to use contraceptive measures both during the study period and within 6 months after its conclusion.\n14. The participant voluntarily consents to receive treatment related to this clinical study and agrees to participate in follow-up assessments.\n\nExclusion Criteria:\n\nPatients who meet any of the following criteria will not be eligible to participate in this study:\n\n1. Known cases of cholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma, and fibrolamellar cell carcinoma; having had an active malignant tumor other than HCC within 5 years or concurrently. Limited-stage tumors that have been cured, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, prostate intraepithelial carcinoma, cervical intraepithelial carcinoma, and breast intraepithelial carcinoma, can be included.\n2. Has previously received anti-cancer treatments targeting metastatic lesions.\n3. The site of extrahepatic metastasis is not the lungs, or there are more than 2 distant metastasized organs (including 2).\n4. Suffering from any severe infection, serious mental or physical illness, or laboratory test abnormalities that are uncontrollable, which may pose an unacceptable risk, negatively impact trial compliance, or affect the administration, distribution, metabolism, and excretion of the investigational drug. Examples include unstable heart disease, chronic kidney disease, poorly controlled diabetes, mood disorders, mental disorders, central nervous system abnormalities, chronic diarrhea, ascites, and pleural effusions requiring treatment.\n5. Suffers from hypertension and cannot achieve adequate control with antihypertensive medication (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg). It is permissible to use antihypertensive treatment to achieve these parameters. Has previously experienced a hypertensive crisis or hypertensive encephalopathy.\n6. Infection with human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) (or active viral hepatitis).\n7. Received experimental treatments from other clinical studies concurrently during the course of this trial.\n8. Long-term use of immunosuppressive agents following organ transplantation.\n9. According to the researchers' assessment, the subject may have other factors that could lead to the forced discontinuation of this study. These include non-compliance with the protocol, the presence of other serious conditions (including mental illnesses) requiring concurrent treatment, significant laboratory abnormalities, a history of substance abuse or drug use, combined with psychological, social, familial, or geographic factors, which could impact the subject's safety or the collection of data and samples.","ALL","18 Years","85 Years",{"count":19,"type":20},32,"ESTIMATED","3 Years","OBSERVATIONAL","1.1. Main Objectives The objective response rate (ORR) determined by the researchers based on RECIST v1.1 was used to evaluate the efficacy of systemic therapy (carrycept combined with apatinib) in combination with or without local treatment (surgery, radiotherapy, or ablation therapy) for patients with advanced hepatocellular carcinoma with pulmonary metastases.\n\n1.2. Secondary objectives Through efficacy indicators such as progression-free survival (PFS) and objective response rate (ORR) determined by researchers based on RECIST v1.1 and mRECIST, evaluate the efficacy of systemic therapy (carrietumab combined with apatinib) combined or not with local treatment (surgery, radiotherapy, or ablation therapy) for patients with advanced hepatocellular carcinoma with pulmonary metastases.\n\nEvaluate the safety of combining systemic therapy (caretuximab-rbsm in combination with apatinib) with or without local treatment (surgery, radiotherapy, or ablation therapy) for patients with advanced hepatocellular carcinoma with pulmonary metastases.\n\n1.3. Exploratory Purpose Evaluate the cumulative duration (the sum of the time spent in a NED state) and the safety of local treatments for patients who have undergone comprehensive treatment and have no detectable active lesions on imaging studies (NED).\n\nExplore the correlation between biomarkers and the efficacy of combined treatment regimens.\n\nExplore the relationship between the number, diameter, and treatment outcomes of pulmonary metastases in hepatocellular carcinoma.",[25],"Hepatecellular Carcinoma","NOT_YET_RECRUITING","2026-03-15",{"date":29,"type":30},"2026-03-19","ACTUAL",{"date":32,"type":20},"2026-03-02",{"date":34,"type":20},"2028-12-31",{"name":36,"class":37},"Xiangya Hospital of Central South University","OTHER",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100626542","phase-1-affordable-made-in-india-microspheres-for-liver-cancer-therapy-100626542","NCT07436988","Affordable Made-in-India Microspheres for Liver Cancer Therapy","Multicentric Study on Indigenous and Affordable Microspheres for Selective Internal Radiation Therapy (SIRT) of Unresectable Liver Cancer","ReLIVE","Inclusion Criteria:\n\n1. Age greater than or equal to 18 years (male or female)\n2. Histologically or radiologically confirmed diagnosis of HCC deemed inoperable\n3. Barcelona Clinic Liver Cancer stage B with ECOG performance status between 0 and 2\n4. At least one measurable lesion with longest diameter greater than or equal to 5 cm on cross sectional imaging\n5. Portal vein thrombosis may be present or absent\n6. Laboratory criteria:\n\n   1. Serum creatinine less than or equal to 1.5 mg per dL\n   2. Total bilirubin less than or equal to 2.0 mg per dL\n   3. AST or ALT less than or equal to 5 times upper limit of normal\n   4. Leukocyte count greater than or equal to 1500 per microliter\n   5. Platelet count greater than or equal to 50000 per microliter\n   6. Prothrombin time less than or equal to 1.3 times control or INR less than or equal to 1.5\n7. Karnofsky performance status greater than 70\n8. Ability and willingness to provide written informed consent for participation in the IEC approved protocol\n\nExclusion Criteria:\n\n1. Women of childbearing potential who are unwilling or unable to use effective contraception or who are pregnant or lactating\n2. Child Pugh class C liver function\n3. Presence of extrahepatic metastases\n4. Severe chronic pulmonary disease with hypoxemia or NYHA class three or four heart failure\n5. Myocardial infarction within the past six months\n6. Unstable arrhythmia or symptomatic cardiac disease\n7. Any other serious uncontrolled illness that in the investigator's opinion would compromise study participation\n8. History of other malignancy except adequately treated basal cell carcinoma or cervical carcinoma in situ within the last five years\n9. Major surgery within four weeks prior to enrolment\n10. Active uncontrolled bacterial infection requiring systemic therapy\n11. Liver rupture, tumor penetration of the liver capsule, tumor invasion of the biliary system, or biliary obstruction\n12. Known allergy or hypersensitivity to any component of the investigational or comparator microspheres\n13. Prior treatment with Selective Internal Radiation Therapy (SIRT)\n14. Estimated overall survival less than one month","90 Years",{"count":48,"type":20},18,"INTERVENTIONAL",[51],"PHASE1","Primary liver tumors, with hepatocellular carcinoma (HCC) accounting for 80%, represent 6% of global cancer incidence and 9% of global cancer-associated mortality.HCC remains the leading causes of cancer-related deaths worldwide, due to late diagnosis. Although local-stage liver tumors are curable with tumor resection or livertransplantation, 65-70% of diagnosed cases are not suitable for resection due to large or multifocal lesions. For these patients, local therapies such as transcatheterarterial chemoembolization (TACE) or selective internal radiation therapy (SIRT) are appropriate at intermediate stages. In cases of advanced and metastatic livertumors, systemic therapies like sorafenib are the standard approach. Selective Intra-arterial Radionuclide Therapy (SIRT) offers a promising treatment for inoperableliver tumors by delivering beta-emitting radiolabeled microspheres directly to tumor sites through the liver's dual blood supply. However, the high cost of standard90Y-microspheres has limited accessibility for patients. This current project aims to develop, optimize, and validate the indigenously prepared microspheres forradiolabeling with 188Re from commercially available generator and indigenously produced radionuclide 177Lu (BARC Mumbai) for SIRT in liver cancer. With hightransformational impact, the current multicentric research will lead to a potentially safe, effective, and promising low-cost SIRT solution for low-income settings.Through collaboration across multiple centers, the study will evaluate the efficacy of microspheres labelled with both radionuclides. By establishing these accessibleSIRT options, this project strives to reduce financial barriers to treatment, advancing the goals of \"Jai Anusandhan\" towards building innovative therapeutics throughcollaborative research project and improving outcomes for patients with limited options.",[25],[55,56,57,58,59,60,61,62],"SIRT","Hepatocellular Carcinoma","188Re-Microspheres","90Y-Theraspheres","RADIANT","Targeted therapy","Liver Cancer","TARE","2026-03-11",{"date":65,"type":30},"2026-03-12",{"date":67,"type":20},"2026-02-15",{"date":69,"type":20},"2028-10-15",{"name":71,"class":37},"Post Graduate Institute of Medical Education and Research, Chandigarh",5,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":49,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100618143","phase-2-ql1706-in-combination-with-bevacizumab-and-ralox-haic-for-hepatocellular-carcinoma-with-vp34-pvtt-100618143","NCT07327788","QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3\u002F4 PVTT","Iparomlimab and Tuvonralimab (QL1706) With Bevacizumab and RALOX Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma (HCC) With Vp3\u002F4 Portain Vein Thrombosis : A Prospective, Multicenter, Phase II Study","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form;\n2. Aged ≥ 18 years, male and female subjects are both eligible;\n3. Clinically or pathologically confirmed hepatocellular carcinoma (HCC), with no prior systemic anti-tumor therapy for HCC (including but not limited to molecular targeted therapy, systemic chemotherapy, immunotherapy such as anti-PD-1\u002FPD-L1\u002FCTLA-4 monoclonal antibodies, etc.);\n4. Complicated with Type VP3 or VP4 portal vein tumor thrombosis (PVTT);\n5. Confirmed to have at least one measurable target lesion by imaging examination during the screening period in accordance with RECIST v1.1 criteria. The measurable lesions should not have received local treatment such as radiotherapy (lesions within the area of previous local treatment can also be selected as target lesions if disease progression is confirmed);\n6. Child-Pugh score ≤ 7 points (Child-Pugh class A-B);\n7. The maximum diameter of liver tumor ≥ 7 cm;\n8. ECOG performance status 0 to 1;\n9. Expected survival time ≥ 12 weeks;\n10. Function of vital organs meeting the following requirements:\n\nAbsolute neutrophil count (ANC) ≥ 1.5×10⁹\u002FL; Platelet count ≥ 50×10⁹\u002FL; Hemoglobin ≥ 90 g\u002FL; Serum albumin ≥ 29 g\u002FL; Bilirubin ≤ 2 × upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 × ULN, alkaline phosphatase (AKP) ≤ 5 × ULN; Serum creatinine ≤ 1.5 × ULN or creatinine clearance rate (CrCl) ≥ 50 mL\u002Fmin calculated by the Cockcroft-Gault formula; 11.Eligible patients with reproductive potential (males and females) must agree to use a reliable contraceptive method (hormonal, barrier method or abstinence) with their partners during the trial and for at least 180 days after the last dose; female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first study medication administration.\n\nExclusion Criteria:\n\n1. Histologically or cytologically confirmed fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocellular carcinoma, mixed hepatocellular carcinoma, etc.;\n2. Active autoimmune disease, or a history of autoimmune disease with potential for recurrence (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism \\[patients whose condition is controllable only with hormone replacement therapy are not excluded\\]); Note: Patients with dermatological diseases that do not require systemic treatment (e.g., vitiligo, psoriasis, alopecia), type 1 diabetes with good glycemic control under insulin therapy, or asthma that achieved complete remission in childhood and requires no intervention in adulthood are eligible for enrollment; patients with asthma requiring medical intervention with bronchodilators are ineligible.\n3. Administration of immunosuppressants or systemic hormonal therapy for immunosuppressive purposes within 2 weeks prior to the first study medication (dose \\> 10 mg\u002Fday prednisone or an equivalent dose of other hormones);\n4. Current interstitial pneumonia or interstitial lung disease, a history of interstitial pneumonia or interstitial lung disease requiring hormonal therapy, or other pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), pneumoconiosis, drug-related pneumonia, idiopathic pneumonia that may interfere with the judgment and management of immune-related pulmonary toxicity; patients with evidence of active pneumonia on screening CT or severe impairment of pulmonary function are excluded. Radiation pneumonitis within the radiation field is permitted;\n5. Confirmed active pulmonary tuberculosis. For subjects with suspected active pulmonary tuberculosis, a definitive diagnosis shall be made based on chest imaging, sputum examination, and clinical symptoms and signs;\n6. Known hypersensitivity to the active ingredients or excipients of the study drugs, or a history of severe hypersensitivity to any other monoclonal antibody or anti-angiogenic targeted drugs;\n7. Known history of central nervous system (CNS) metastasis or hepatic encephalopathy;\n8. A history of allogeneic stem cell transplantation or solid organ transplantation;\n9. Moderate to severe ascites with clinical symptoms requiring therapeutic paracentesis or drainage (except for patients with only a small amount of ascites shown by imaging without clinical symptoms), or uncontrolled moderate to large pleural effusion or pericardial effusion;\n10. Severe cardiovascular and cerebrovascular diseases, including but not limited to:\n\n(1) Severe cardiac rhythm or conduction abnormalities (e.g., ventricular or supraventricular arrhythmias requiring clinical intervention, grade Ⅱ-Ⅲ atrioventricular block), QTcF interval ≥ 450 ms (males) or QTcF interval ≥ 470 ms (females) (if the QTcF interval is abnormal at screening, two additional tests shall be performed at an interval of at least 5 minutes, and the average value shall be taken); unstable angina pectoris, etc.; (2) Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, transient ischemic attack (TIA) or other grade 3 and above cardiovascular and cerebrovascular events within 6 months prior to the first study medication; (3) New York Heart Association (NYHA) cardiac function classification ≥ grade II or left ventricular ejection fraction (LVEF) \\\u003C 50%; (4) Poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg after treatment with two or more antihypertensive drugs); 11.Coagulation dysfunction (INR \\> 2.0, prothrombin time (PT) prolonged by more than 6 seconds), with obvious bleeding tendency or other evidence of major coagulation disorders: clinically significant hemoptysis or tumor bleeding of any cause within 2 weeks prior to the first study medication; a history of thrombosis or embolism within 6 months prior to the first study medication; therapeutic anticoagulant therapy (except low-molecular-weight heparin) within 2 weeks prior to the first study medication; or antiplatelet therapy (e.g., aspirin \\> 325 mg\u002Fday, clopidogrel \\> 75 mg\u002Fday, dipyridamole, ticlopidine, cilostazol) within 10 days prior to the first study medication, or patients requiring long-term antiplatelet therapy; patients with metastatic lesions invading large blood vessels, respiratory tract or middle mediastinum with a significant risk of bleeding; 12.A history of esophageal or gastric variceal bleeding caused by portal hypertension within 6 months prior to the first study medication; confirmed severe varices by endoscopy within 3 months prior to the first study medication; or evidence of portal hypertension (including splenomegaly detected by imaging) with a high risk of bleeding assessed by the investigator (including moderate to severe esophagogastric varices with bleeding risk, active local peptic ulcer, and persistent positive fecal occult blood, which require gastroscopy to exclude patients with \"red signs\". Patients with a history of \"red signs\" on gastroscopy are excluded); 13.Any life-threatening bleeding event within 3 months prior to the first study medication, including those requiring blood transfusion, surgery or local treatment, and continuous drug therapy; 14.A history of abdominal fistula, gastrointestinal perforation or abdominal abscess within 6 months prior to the first study medication; 15.A history of intestinal obstruction and\u002For clinical signs or symptoms of gastrointestinal obstruction within 6 months prior to the first study medication, including incomplete obstruction related to the primary disease or requiring routine parenteral hydration, parenteral nutrition or tube feeding; 16.Severe unhealed wounds, active ulcers or untreated fractures; 17.Urinalysis showing urine protein ≥ ++ with a confirmed 24-hour urine protein excretion \\> 1.0 g; 18.Severe infection within 4 weeks prior to the first study medication (including but not limited to hospitalization due to infection, bacteremia or severe pneumonia complications); active infection requiring oral or intravenous therapeutic antibiotics within 2 weeks prior to the first study medication (patients receiving prophylactic antibiotics, e.g., for prevention of urinary tract infection or acute exacerbation of chronic obstructive pulmonary disease, are eligible); unexplained fever ≥ 38.5℃ within 7 days prior to medication administration, or baseline white blood cell count \\> 15×10⁹\u002FL; 19.Congenital or acquired immune deficiency (e.g., HIV-infected patients), or confirmed active syphilis infection; 20.A history of other malignant tumors except HCC within 5 years prior to the first study medication or concurrent malignant tumors. Patients with the following cured localized tumors are eligible for enrollment: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, carcinoma in situ of the cervix, carcinoma in situ of the breast, etc.; 21.Hepatic surgery, local treatment for HCC or investigational drug therapy within 4 weeks prior to the first study medication; administration of traditional Chinese medicine preparations with anti-HCC effects within 2 weeks prior to the first study medication; or toxic reactions caused by previous treatment (except alopecia) that have not recovered to ≤ grade 1 (per NCI-CTCAE v5.0); 22.Administration of drugs with immunomodulatory effects (including but not limited to interferon, interleukin) within 2 weeks prior to the first study medication; 23.Participation in other clinical studies and administration of other investigational drugs within 4 weeks prior to the first study medication; 24.Administration of live attenuated vaccines within 4 weeks prior to the first study medication, or anticipated need for such vaccination during the study treatment or within 90 days after the last study medication; 25.Major surgery (except for diagnostic purposes) within 4 weeks prior to the first study medication, or anticipated major surgery during the study period (major surgery is defined as surgery performed under general anesthesia that requires a recovery period of at least 3 weeks before initiation of study drug treatment); tissue biopsy or other minor surgical procedures within 7 days prior to the first study medication, except for venous catheterization for intravenous infusion; 26.Pregnant or lactating women, or women of childbearing potential who refuse to take contraceptive measures; 27.Other factors judged by the investigator that may affect the study results or lead to forced early termination of the study, such as alcoholism, drug abuse, other severe diseases (including mental illness) requiring combined treatment, severe abnormal laboratory tests, or family\u002Fsocial factors that may affect patient safety.",{"count":81,"type":20},38,[83],"PHASE2","The goal of this prospective, single-arm, multi-center Phase II clinical trial is to evaluate the clinical efficacy and safety of QL1706 combined with bevacizumab and RALOX hepatic artery infusion chemotherapy in treating liver cancer patients with VP3\u002F4 portal vein tumor thrombus. It will also explore molecular biomarkers that predict the efficacy of this combined therapy.\n\nThe main questions it aims to answer are:\n\nWhat is the progression-free survival (PFS) of patients treated with this regimen? What are the objective response rate (ORR), disease control rate (DCR), and overall survival (OS) of these patients? What is the safety and tolerability profile of this combined treatment? Which molecular biomarkers can predict the efficacy of this therapy? Eligible subjects (who have signed informed consent) will receive RALOX hepatic artery infusion chemotherapy plus QL1706 (7.5mg, intravenous infusion every 3 weeks) and bevacizumab (15mg\u002Fkg, intravenous infusion every 3 weeks), with 3 weeks as one treatment cycle. Treatment will continue until a protocol-specified discontinuation event occurs. After treatment, subjects will undergo post-treatment safety follow-up and survival follow-up; those who discontinue treatment for reasons other than disease progression or death will also have tumor progression follow-up.",[25,86,87,88,89,90],"RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin","Bevacizumab","Type VP3\u002F4 Portal Vein Tumor Thrombosis","Iparomlimab and Tuvonralimab Injection","QL1706","RECRUITING","2026-01-11",{"date":94,"type":30},"2026-01-13",{"date":96,"type":20},"2025-12-25",{"date":98,"type":20},"2028-12-30",{"name":100,"class":37},"Nanfang Hospital, Southern Medical University",1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":101},"100597737","ai-based-prediction-of-hcc-recurrence-patterns-after-resection-apar-100597737","NCT07062380","AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)","Prospective Validation of Multimodal Deep Learning Models for Predicting Recurrence Patterns in Early-Stage Hepatocellular Carcinoma After Resection: A Natural Treatment Cohort Stratification Study","Inclusion Criteria:\n\n* Aged 18-75 years, regardless of gender.\n* BCLC stage 0-A, scheduled for curative liver resection.\n* Preoperative clinical diagnosis of hepatocellular carcinoma (HCC).\n* Availability of dynamic contrast-enhanced MRI within 1 month before surgery, with acceptable image quality.\n* Child-Pugh liver function score ≤7.\n* ECOG Performance Status (PS) 0-1.\n* No severe organic diseases of the heart, lungs, brain, or other vital organs.\n\nExclusion Criteria:\n\n* Concurrent other malignancies (except cured non-melanoma skin cancer or cervical carcinoma in situ).\n* Postoperative pathology confirms non-HCC diagnosis.\n* Pregnant or lactating women.\n* History of organ transplantation.\n* Inability to comply with the study protocol or follow-up schedule.","75 Years",{"count":111,"type":20},353,"This observational study aims to validate a deep learning model for predicting aggressive recurrence patterns in patients with early-stage liver cancer (HCC) after surgery.\n\nThe main question it aims to answer is: Can the AI model accurately identify patients at high risk of cancer recurrence within 2 years after surgery? Participants will provide clinical data and undergo standard surgery, followed by 2-year imaging surveillance. Their data will be used for both AI prediction and validation of recurrence patterns.",[25,114],"Hepatectomy","2025-08-26",{"date":117,"type":30},"2025-09-03",{"date":119,"type":30},"2025-06-10",{"date":121,"type":20},"2028-06-10",{"name":123,"class":37},"Tongji Hospital"]